dili

In the world of pharmacovigilance, few adverse events command as much respect and caution as Drug-Induced Liver Injury (DILI). It is a leading cause of acute liver failure in the Western world and remains the single most frequent safety-related reason for the withdrawal of drugs from the market. Whether you are in clinical development or […]

The recent revocation of the Ulipristal licence to indicate uterine fibroids has reminded the Pharmacovigilance community about the importance of Drug-induced liver injury, or DILI. Incidentally, DILI is one of the most typical reasons for product withdrawals. Drug-induced liver injury (DILI) is uncommon but a potentially fatal cause of liver disease associated with medications and […]